These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17920160)

  • 61. Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease.
    Steen Jensen C; Portelius E; Siersma V; Høgh P; Wermuth L; Blennow K; Zetterberg H; Waldemar G; Gregers Hasselbalch S; Hviid Simonsen A
    Dement Geriatr Cogn Disord; 2016; 42(3-4):146-158. PubMed ID: 27643858
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials.
    Dumurgier J; Laplanche JL; Mouton-Liger F; Lapalus P; Indart S; Prévot M; Peoc'h K; Hugon J; Paquet C
    J Neurol; 2014 Jun; 261(6):1187-95. PubMed ID: 24728335
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.
    Skouras S; Torner J; Andersson P; Koush Y; Falcon C; Minguillon C; Fauria K; Alpiste F; Blenow K; Zetterberg H; Gispert JD; Molinuevo JL;
    Brain; 2020 Mar; 143(3):976-992. PubMed ID: 32091109
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
    Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
    Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
    [TBL] [Abstract][Full Text] [Related]  

  • 65. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.
    Schuff N; Woerner N; Boreta L; Kornfield T; Shaw LM; Trojanowski JQ; Thompson PM; Jack CR; Weiner MW;
    Brain; 2009 Apr; 132(Pt 4):1067-77. PubMed ID: 19251758
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
    Stefanova E; Blennow K; Almkvist O; Hellström-Lindahl E; Nordberg A
    Neurosci Lett; 2003 Feb; 338(2):159-63. PubMed ID: 12566177
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Assessment of apolipoprotein E genotype for β-amyloid status prediction.
    Peña-Bautista C; Álvarez-Sánchez L; García L; Baquero M; Cháfer-Pericás C
    Curr Alzheimer Res; 2021; 18(13):1032-1040. PubMed ID: 34951383
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels.
    Maxwell TJ; Corcoran C; Del-Aguila JL; Budde JP; Deming Y; Cruchaga C; Goate AM; Kauwe JSK;
    Alzheimers Res Ther; 2018 Aug; 10(1):86. PubMed ID: 30153862
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
    Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
    J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
    Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.
    Voyle N; Patel H; Folarin A; Newhouse S; Johnston C; Visser PJ; Dobson RJ; Kiddle SJ;
    J Alzheimers Dis; 2017; 55(4):1417-1427. PubMed ID: 27834776
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
    Popp J; Lewczuk P; Frommann I; Kölsch H; Kornhuber J; Maier W; Jessen F
    J Alzheimers Dis; 2010; 22(2):459-68. PubMed ID: 21084733
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.
    Andreasson U; Lautner R; Schott JM; Mattsson N; Hansson O; Herukka SK; Helisalmi S; Ewers M; Hampel H; Wallin A; Minthon L; Hardy J; Blennow K; Zetterberg H
    Mol Psychiatry; 2014 Feb; 19(2):148-9. PubMed ID: 23419830
    [No Abstract]   [Full Text] [Related]  

  • 76. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
    Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
    J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Apo-Eε4 allele in conjunction with Aβ42 and tau in CSF: biomarker for Alzheimer's disease.
    Kandimalla RJ; Prabhakar S; Binukumar BK; Wani WY; Gupta N; Sharma DR; Sunkaria A; Grover VK; Bhardwaj N; Jain K; Gill KD
    Curr Alzheimer Res; 2011 Mar; 8(2):187-96. PubMed ID: 21222606
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
    Lasser RA; Dukoff R; Levy J; Levin R; Lehtimäki T; Seubert P; Sunderland T
    Int J Geriatr Psychiatry; 1998 Nov; 13(11):767-74. PubMed ID: 9850873
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.
    Alexopoulos P; Guo LH; Kratzer M; Westerteicher C; Kurz A; Perneczky R
    Dement Geriatr Cogn Disord; 2011; 32(3):164-70. PubMed ID: 21997402
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42.
    Sleegers K; Bettens K; De Roeck A; Van Cauwenberghe C; Cuyvers E; Verheijen J; Struyfs H; Van Dongen J; Vermeulen S; Engelborghs S; Vandenbulcke M; Vandenberghe R; De Deyn PP; Van Broeckhoven C;
    Alzheimers Dement; 2015 Dec; 11(12):1452-1460. PubMed ID: 26086184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.